Replies to post #338 on Otonomy Inc. fka OTIC

[Blade$dream]

$OTIC Anticipated Upcoming Milestones:

Meet with the FDA during the first quarter of 2018 to review the AVERTS Phase 3 clinical trial data and discuss clinical requirements for OTIVIDEX registration in patients with Ménière’s disease.

Complete the pipeline review and prioritization, and present a development plan for multiple clinical and preclinical programs in the first quarter of 2018.